Search

Author/Creator Ghia, P.

1. A MRD‐GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY). (June 2017)

Authors:
Ghia, P.; Scarfò, L.; Coscia, M.; Sancetta, R.; Ferrario, A.; Tedeschi, A.; Farina, L.; Laurenti, L.; Orlandi, E.; Reda, G.; Motta, M.; Carlo Stella, C.; Massaia, M.; Quaresmini, G.; Rossini, F.; Ladetto, M.; Gaidano, G.; Rossi, V.; Montillo, M.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
426
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. (12th June 2019)

Authors:
Ghia, P.; Pluta, A.; Wach, M.; Lysak, D.; Kozak, T.; Simkovic, M.; Kaplan, P.; Kraychok, I.; Illes, A.; De La Serna, J.; Dolan, S.; Campbell, P.; Musuraca, G.; Jacob, A.; Avery, E.J.; Lee, J.H.; Chen, T.; Liang, W.; Patel, P.; Jurczak, W.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
86
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES. (12th June 2019)

Authors:
Flinn, I.W.; Davids, M.S.; Hillmen, P.; Montillo, M.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Jäger, U.; Ghia, P.; Stilgenbauer, S.; Lustgarten, S.; Weaver, D.T.; Youssoufian, H.; Cymbalista, F.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
213
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL. (12th June 2019)

Authors:
Ghia, P.; Flinn, I.W.; Lamanna, N.; Montillo, M.; Illés, Á.; Etienne, G.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Offner, F.; Bosch, F.; Davids, M.S.; Jäger, U.; Cymbalista, F.; Weaver, D.T.; Lustgarten, S.; Youssoufian, H.; Stilgenbauer, S.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
214
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. EFFECT OF SINGLE‐AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (June 2017)

Authors:
Tam, C.S.; Byrd, J.C.; O'Brien, S.; Coutre, S.; Barr, P.M.; Furman, R.R.; Kipps, T.J.; Burger, J.A.; Stevens, D.; Sharman, J.; Ghia, P.; Flinn, I.; Zhou, C.; Ninomoto, J.; James, D.F.; Wierda, W.G.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
233
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2. (17th June 2021)

Authors:
Coutre, S. E.; Barr, P. M.; Owen, C.; Robak, T.; Tedeschi, A.; Bairey, O.; Burger, J. A.; Hillmen, P.; Devereux, S.; Grosicki, S.; McCarthy, H.; Li, J.; Simpson, D.; Offner, F.; Moreno, C.; Dai, S.; Szoke, A.; Dean, J. P.; Kipps, T. J.; Ghia, P.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA. (12th June 2019)

Authors:
Tedeschi, A.; Burger, J.; Barr, P.M.; Robak, T.; Owen, C.; Ghia, P.; Bairey, O.; Hillmen, P.; Coutre, S.; Devereux, S.; Grosicki, S.; McCarthy, H.; Li, J.; Simpson, D.; Offner, F.; Moreno, C.; Dai, S.; Lal, I.; Dean, J.P.; Kipps, T.J.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
103
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. (23rd June 2022)

Authors:
Eyre, T. A.; Wang, M. L.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Vandenberghe, E.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; Wang, Y.; Coombs, C. C.; Flinn, I.; Lewis, D.; Le Gouill, S.; Gandhi, M.; Chay, C.; Palomba, M. L.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
991
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗